Latest News and Press Releases

OXURION announces its presence at the Paris SmallCapevent on March 28, 2024. Leuven, BELGIUM - March 25, 2024 - 7:00 p.m, Oxurion NV (Euronext Brussels : OXUR), a Leuven-based biopharmaceutical...

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – March 22, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company...

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR...

Dublin, March 19, 2024 (GLOBE NEWSWIRE) -- The "Global Diabetic Macular Edema Treatment Market by Treatment (Corticosteroid Injections, Drugs, Laser Treatment), End-User (Hospitals, Ophthalmology...

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – March 13, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company...

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – March 07, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company...

Oxurion Receives EUR 300,000 in the framework of the Atlas Funding ProgramTenth tranche fully issued and paid-up Leuven, BELGIUM, 05 March – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a...

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR...

Industry Leader and Retina Expert, Pravin U. Dugel, MD, Becomes Executive Chair Jeffrey S. Heier, MD to become Chief Scientific Officer, Peter K. Kaiser, MD to be Medical Director, and Sanjay...

Leuven, BELGIUM, 22 January 2024 9:00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announced today its new corporate strategy to further...